Dronedarone for Atrial Fibrillation. Have We Expanded the Antiarrhythmic Armamentarium?

Journal of the American College of Cardiology

Volumn 55, Issue 15, 2010, Pages 1569-1576

  Singh, David ^a   Cingolani, Eugenio ^a   Diamond, George A ^a   Kaul, Sanjay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiarrhythmic agents; atrial fibrillation; atrial flutter; heart failure

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO;

ANTIARRHYTHMIC ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; VOMITING;

AMIODARONE; ATRIAL FIBRILLATION; HEART RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 77950331396     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.071     Document Type: Review

References (28)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001) 2370-2375
2. Wattigney W.A., Mensah G.A., and Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108 (2003) 711-716
3. Buechner J.S. Deaths and hospitalizations related to atrial fibrillation, 1999-2001. Med Health R I 86 (2003) 183-185
4. Khairallah F., Ezzedine R., Ganz L.I., London B., and Saba S. Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. Am J Cardiol 94 (2004) 500-504
5. Initial National Priorities for Comparative Effectiveness Research. List of Priorities. Institute of Medicine of the National Academies. www.iom.edu/?id=71032 Accessed September 29, 2009
6. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
7. Hagens V.E., Ranchor A.V., Van Sonderen E., et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 43 (2004) 241-247
8. Dronedarone Approval Letter (2009), Food and Drug Administration, Rockville, MD. www.fda.gov Accessed September 29, 2009
9. Zimetbaum P.J. Dronedarone for atrial fibrillation-an odyssey. N Engl J Med 360 (2009) 1811-1813
10. Sun W., Sarma J.S., and Singh B.N. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 100 (1999) 2276-2281
11. Varro A., Takacs J., Nemeth M., et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 133 (2001) 625-634
12. Cardiovascular and Renal Drugs Advisory Committee Meeting. NDA 22-425, Dronedarone 400 Milligrams Oral Tablets (2009), Food and Drug Administration, Rockville, MD. www.fda.gov Accessed September 29, 2009
13. Tschuppert Y., Buclin T., Rothuizen L.E., et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 64 (2007) 785-791
14. Touboul P., Brugada J., Capucci A., Crijns H.J., Edvardsson N., and Hohnloser S.H. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24 (2003) 1481-1487
15. Singh B.N., Connolly S.J., Crijns H.J., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357 (2007) 987-999
16. Davy J.M., Herold M., Hoglund C., et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study. Am Heart J 156 (2008) 527.e1-527.e9
17. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008) 2678-2687
18. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360 (2009) 668-678
19. Coplen S.E., Antman E.M., Berlin J.A., Hewitt P., and Chalmers T.C. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82 (1990) 1106-1116
20. Doyle J.F., and Ho K.M. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 84 (2009) 234-242
21. Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
22. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 42 (2003) 20-29
23. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 (2000) 913-920
24. Dronedarone Label (2009), Food and Drug Administration, Rockville, MD. www.fda.gov Accessed September 29, 2009
25. Transcript for March 18, 2009, Meeting of the Cardiovascular and Renal Drugs Advisory Committee (PDF-558KB). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM151343.pdf Accessed September 29, 2009
26. Diamond G.A., Bax L., and Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147 (2007) 578-581
27. Dofetilide Approval Letter (1999), Food and Drug Administration, Rockville, MD. www.fda.gov Accessed September 29, 2009
28. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48 (2006) 854-906